How GDPR Will Transform The Disclosure Landscape

This webinar happened on 31 May, 2017
Dont worry if you missed it, we have it recorded for you.

As they enter the third quarter of 2017, are pharmaceutical companies in Europe prepared for the additional demands imposed by GDPR? Have they laid a strong-enough framework to collect and manage consent to be ready for the limitations that will come as a result of the GDPR? What can they do to equip themselves for a more conservative reporting regime?

Takeaway From This Webinar:

  • Differences between the EU Transparency Directive and GDPR
  • The ‘right to erasure’ and implications for publishing spend data
  • The ‘right to forget’ and its relevant application for pharma companies in EU
  • Dos and Don’ts of disclosure when preparing for GDPR


Following the promulgation of GDPR in May 2018, the role of Transparency and Compliance professionals will gain more complexity. This webinar is an attempt to share findings and best practices related to pharma spend disclosure in the EU, to resolve some of that complexity, and bring more homogeneity to the data publication process across the region.

Who Should Attend?

Senior and mid-level Transparency, Corporate Compliance and Legal Professionals from the pharmaceutical manufacturing industry in Europe.


Elisabeth Kohoutek
King & Spalding

Maite Vazquez Calo
Independent member of the Board of Directors
Cooperative Group Cajamar

Co-Speaker & Moderator

Ned Mumtaz
Practice Leader Life Science